Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice

6 Jun 2015

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunotherapy and Immune Responses
Share to Monoclonal and Polyclonal Antibodies Research
Share to vaccines and immunoinformatics approaches

Source

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Identifiers

PMID: 26052074
DOI: 10.1053/j.gastro.2015.05.055

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 22 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in MicePMID 26052074Read ↗

The therapeutic landscape for cells engineered with chimeric antigen receptorsSemantic proximity Read ↗

Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against hepatocellular carcinomaSemantic proximity Read ↗

G9a/GLP inhibition during ex vivo lymphocyte expansion increases in vivo cytotoxicity of engineered TCR-T cells against hepatocellular carcinomaSemantic proximity Read ↗

Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and BenefitSemantic proximity Read ↗

G9a/GLP inhibition during ex vivo lymphocyte expansion increases in vivo cytotoxicity of engineered T cells against hepatocellular carcinomaSemantic proximity Read ↗

Chimeric antigen receptor T cell therapy for autoimmune diseaseSemantic proximity Read ↗

Characterization of T Cell Receptors Engineered for High Affinity Against Toxic Shock Syndrome Toxin-1Semantic proximity Read ↗

Visualizing cell–cell communication using synthetic notch activated MRISemantic proximity Read ↗

Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.Semantic proximity Read ↗

Chimeric HLA antibody receptor T cells for targeted therapy of antibody-mediated rejection in transplantation.Semantic proximity Read ↗

Development of a pre-glycoengineered CHO-K1 host cell line for the expression of antibodies with enhanced Fc mediated effector functionSemantic proximity Read ↗

Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.